Unknown

Dataset Information

0

Chemokine Network and Overall Survival in TP53 Wild-Type and Mutant Ovarian Cancer.

ABSTRACT: Ovarian cancer (OC) has the highest mortality rate among gynecological malignancies. Because chemokine network is involved in OC progression, we evaluated associations between chemokine expression and survival in tumor suppressor protein p53 (TP53) wild-type (TP53WT) and mutant (TP53m) OC datasets. TP53 was highly mutated in OC compared to other cancer types. Among OC subtypes, CXCL14 was predominantly expressed in clear cell OC, and CCL15 and CCL20 in mucinous OC. TP53WT endometrioid OC highly expressed CXCL14 compared to TP53m, showing better progression-free survival but no difference in overall survival (OS). TP53m serous OC highly expressed CCL8, CCL20, CXCL10 and CXCL11 compared to TP53WT. CXCL12 and CCL21 were associated with poor OS in TP53WT serous OC. CXCR2 was associated with poor OS in TP53m serous OC, while CXCL9, CCL5, CXCR4, CXCL11, and CXCL13 were associated with better OS. Taken together, specific chemokine signatures may differentially influence OS in TP53WT and TP53m OC.

SUBMITTER: Ignacio RMC 

PROVIDER: S-EPMC6117514 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Chemokine Network and Overall Survival in <i>TP53</i> Wild-Type and Mutant Ovarian Cancer.

Ignacio Rosa Mistica C RMC   Lee Eun-Sook ES   Wilson Andrew J AJ   Beeghly-Fadiel Alicia A   Whalen Margaret M MM   Son Deok-Soo DS  

Immune network 20180813 4

Ovarian cancer (OC) has the highest mortality rate among gynecological malignancies. Because chemokine network is involved in OC progression, we evaluated associations between chemokine expression and survival in tumor suppressor protein p53 (<i>TP53</i>) wild-type (<i>TP53</i>WT) and mutant (<i>TP53</i>m) OC datasets. <i>TP53</i> was highly mutated in OC compared to other cancer types. Among OC subtypes, CXCL14 was predominantly expressed in clear cell OC, and CCL15 and CCL20 in mucinous OC. <i  ...[more]

Similar Datasets

Unknown Poor survival with wild-type TP53 ovarian cancer?
| S-EPMC4059202 | biostudies-literature
Clinical Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type
| 2287507 | ecrin-mdr-crc
Unknown Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.
| S-EPMC4527847 | biostudies-literature
Unknown Wild-type tumor repressor protein 53 (Trp53) promotes ovarian cancer cell survival.
| S-EPMC3320246 | biostudies-literature
Unknown Kevetrin induces apoptosis in TP53 wild‑type and mutant acute myeloid leukemia cells.
| S-EPMC7448420 | biostudies-literature
Unknown Impact of prolonged and early bevacizumab treatment on the overall survival of EGFR-mutant and EGFR-wild type nonsquamous non-small cell lung cancer.
| S-EPMC6275835 | biostudies-literature
Unknown TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
| S-EPMC8565061 | biostudies-literature
Unknown Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival.
| S-EPMC4656807 | biostudies-other
Unknown Wild-Type TP53 Predicts Poor Prognosis in Patients with Gastric Cancer.
| S-EPMC8694034 | biostudies-literature
Unknown Activating STING1-dependent immune signaling in <i>TP53</i> mutant and wild-type acute myeloid leukemia.
| S-EPMC9271208 | biostudies-literature